NKGN · As filed with the SEC
NKGen Biotech balance sheet, by quarter
The statement as NKGen Biotech presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED BALANCE SHEETS · USD thousands
| USD thousands | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 | Q3 2023 Sep 30, 2023 | Q2 2023 Jun 30, 2023 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 6 | 106 | 8 | 79 | 34 | 26 | 8,786 | 41.46 |
| Prepaid expenses | — | — | — | — | — | — | — | 34,179 |
| Accounts receivable | — | — | — | — | — | 0 | 0 | — |
| Restricted cash | 23 | 129 | 229 | 250 | 250 | 250 | 250 | — |
| Prepaid expenses and other current assets | 2,352 | 2,224 | 674 | 920 | 1,323 | 1,654 | 1,313 | — |
| Total current assets | 2,381 | 2,459 | 911 | 1,249 | 1,607 | 1,930 | 10,349 | 75.64 |
| Cash and investments held in Trust Account | — | — | — | — | — | — | — | 63,529,895 |
| Property and equipment, net | 13,024 | 13,297 | 13,576 | 13,856 | 14,136 | 14,459 | 14,670 | — |
| Operating lease right-of-use asset, net | 341 | 379 | 415 | 450 | 482 | 0 | 89 | — |
| Capitalized software, net | 96 | 96 | 93 | 93 | 91 | 92 | 90 | — |
| Total assets | 15,842 | 16,231 | 14,995 | 15,648 | 16,316 | 16,481 | 25,198 | 63,605.53 |
| Liabilities and Stockholders’ Deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | — | — | — | — | — | — | — | 163,344 |
| Franchise tax payable | — | — | — | — | — | — | — | 66,255 |
| Accrued expenses | — | — | — | — | — | — | — | 5,050,540 |
| Accounts payable and accrued expenses | 16,738 | 15,668 | 16,608 | 15,104 | 15,313 | 13,395 | 12,965 | — |
| Forward purchase derivative liabilities | 175 | 148 | — | — | 10,085 | 15,804 | 20,201 | — |
| Forward purchase derivative liabilities | — | — | 118 | 10,511 | — | — | — | — |
| Tranche Rights | — | — | 70 | 4,336 | — | — | — | — |
| Convertible debt | — | — | — | — | — | 0 | 0 | — |
| Convertible promissory notes, due to related parties | — | — | — | — | — | 0 | 0 | — |
| Convertible 12% promissory notes | — | — | — | — | 728 | — | — | — |
| Convertible Promissory Notes | — | — | 9,709 | 7,259 | — | — | — | — |
| Convertible Promissory Notes | 18,303 | 32,410 | — | — | — | — | — | — |
| Convertible Bridge Loans | 196 | 244 | — | 25 | 631 | — | — | — |
| Bridge loans | — | — | — | — | 215 | — | — | — |
| Related party loans | 4,000 | 4,000 | 5,000 | 5,000 | 5,000 | — | — | — |
| Revolving line of credit | 4,257 | 5,257 | 4,991 | 4,991 | 4,991 | 4,991 | 4,931 | — |
| Related party loans | — | — | — | — | — | 5,000 | 300 | — |
| Obligation to issue common stock | — | — | — | 3,617 | — | — | — | — |
| Operating lease liability, current | 154 | 154 | 154 | 154 | 154 | 0 | 96 | — |
| Other current liabilities | 65 | 90 | 468 | 411 | 366 | 262 | 355 | 32.81 |
| Income tax payable | — | — | — | — | — | — | — | 572,146 |
| Convertible promissory note - related party | — | — | — | — | — | — | — | 416,710 |
| Total current liabilities | 43,888 | 57,971 | 37,118 | 51,408 | 37,483 | 39,452 | 38,848 | 6,301.80 |
| Derivative warrant liability | — | — | — | — | — | — | — | 944,310 |
| Deferred underwriting commissions in connection with the initial public offering | — | — | — | — | — | — | — | 2,102,284 |
| Related party loans | — | — | — | — | — | — | 5,000 | — |
| Derivative warrant liabilities | 10,995 | 17,073 | 14,008 | 23,236 | 23,360 | 25,759 | 12,255 | — |
| Senior convertible promissory notes, due to related parties | 11,077 | 10,841 | 10,604 | 10,372 | 10,147 | 9,930 | 9,707 | — |
| Operating lease liability, non-current | 206 | 246 | 282 | 316 | 348 | — | — | — |
| Deferred tax liabilities | 8 | 8 | 33 | 33 | 33 | 33 | 26 | — |
| Total liabilities | 66,174 | 86,139 | 62,045 | 85,365 | 71,371 | 75,174 | 65,836 | 9,348.40 |
| Common stock subject to possible redemption | — | — | — | — | — | — | — | 62,796,284 |
| Stockholders’ deficit: | ||||||||
| Common stock, $0.0001 par value; 500,000,000 authorized shares as of March 31, 2025 and December 31, 2024; 51,306,712 and 44,238,754 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 5 | 4 | 4 | 3 | 2 | 2 | 2 | — |
| Common stock not subject to possible redemption | — | — | — | — | — | — | — | 429 |
| Additional paid-in capital | 140,911 | 136,686 | 130,199 | 124,586 | 122,844 | 121,727 | 120,799 | — |
| Subscription receivable | (182) | (182) | (251) | (10,706) | (10,389) | (17,792) | (32,915) | — |
| Receivable from shareholder | — | 0 | 0 | 0 | 0 | (500) | — | — |
| Accumulated deficit | (191,066) | (206,416) | (177,002) | (183,600) | (167,512) | (162,130) | (128,524) | (8,539.58) |
| Total stockholders’ deficit | (50,332) | (69,908) | (47,050) | (69,717) | (55,055) | (58,693) | (40,638) | (8,539.15) |
| Total liabilities and stockholders’ deficit | 15,842 | 16,231 | 14,995 | 15,648 | 16,316 | 16,481 | 25,198 | 63,605.53 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.
Data on this page was fetched . The filing on SEC.gov is the record.